By Lori Solomon HealthDay Reporter>MONDAY, Oct. 16, 2023 -- At five years, five-fraction stereotactic body radiotherapy (SBRT) is noninferior to control radiotherapy for biochemical/clinical failure (BCF) in men with localized prostate cancer (LPCa), according to a study presented at the annual meeting of the American Society for Radiation Oncology (ASTRO), held from Oct.

作者：Lori Solomon HealthDay记者>2023年10月16日星期一-五年后，五分立体定向放射治疗（SBRT）不逊于控制局限性前列腺癌（LPCa）男性生化/临床失败（BCF）的放射治疗，根据10月举行的美国放射肿瘤学会（ASTRO）年会上发表的一项研究。

1 to 4 in San Diego.Nicholas van As, M.D., from the Royal Marsden NHS Foundation Trust in London, and colleagues randomly assigned (1:1) men with LPCa, stage T1 to T2 to SBRT (433 patients; 36.25 Gy/5f in one to two weeks) or control radiotherapy (CRT; 441 patients; 78 Gy/39f over 7.5 weeks or 62 Gy/20f in four weeks) to the planning target volume.The researchers found that at a median follow-up of 73.1 months, the five-year BCF event-free rate was 94.6 percent for control radiotherapy and 95.7 percent for the SBRT groups.

来自伦敦皇家马斯登NHS基金会信托基金的Nicholas van As博士和同事随机分配（1:1）LPCa男性，T1〜T2期SBRT（433例患者，36.25 Gy/5f在一到两周）或对照放疗（CRT；441例患者；78 Gy/39f超过7.5周或62 Gy/20f在四周）到计划目标量。研究人员发现，在中位随访73.1个月时，对照放疗的5年BCF无事件发生率为94.6%，SBRT组为95.7%。

SBRT was noninferior to CRT (unadjusted hazard ratio, 0.74; 90 percent confidence interval, 0.47 to 1.17; P-value for noninferiority = 0.007). Compared with the control group, the estimated absolute differences in the proportion of patients who were event-free in the SBRT group at five years was 1.36 percent.

SBRT不逊于CRT（未调整风险比为0.74；90%置信区间为0.47〜1.17；非劣效性P值为0.007）。与对照组相比，SBRT组5年无事件发生率为1.36%。

Radiation Therapy Oncology Group (RTOG) grade 2 or worst (G2+) genitourinary toxicity at five years occurred in 3.2 percent of control patients and 5.5 percent of patients in the SBRT group. For RTOG G2+ gastrointestinal toxicity, there was no significant difference observed between the groups.'The outcomes for patients in both study arms were better than we expected,' van As said in a statement.

放射治疗肿瘤组（RTOG）2年或最差（G2+）泌尿生殖系统毒性发生率为3.2%，SBRT组为5.5%。对于RTOG G2+胃肠道毒性，两组之间没有观察到显着差异van在一份声明中说，两个研究组患者的结果都比我们预期的要好。

'To be able to sit with a patient and say, 'We can treat you with a low-toxicity treatment in five days, and your chance of keeping the cancer at bay for five years is 96 percent' -- it.

“能够和病人坐在一起，说：”我们可以在五天内用低毒治疗来治疗你，你将癌症控制五年的机会是96%’-它。